Napoleon Rutledge, Jr. Sells 133 Shares of McKesson (NYSE:MCK) Stock

McKesson Corporation (NYSE:MCK) CAO Napoleon Rutledge, Jr. sold 133 shares of McKesson stock in a transaction on Friday, June 5th. The stock was sold at an average price of $764.00, for a total value of $101,612.00. Following the completion of the sale, the chief accounting officer directly owned 632 shares of the company’s stock, valued at approximately $482,848. The trade was a 17.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

McKesson Price Performance

Shares of MCK opened at $783.71 on Wednesday. McKesson Corporation has a one year low of $637.00 and a one year high of $999.00. The firm has a market capitalization of $94.20 billion, a P/E ratio of 20.37, a PEG ratio of 1.26 and a beta of 0.31. The business has a fifty day moving average of $802.84 and a 200 day moving average of $847.76.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The company had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same quarter in the previous year, the company posted $10.12 earnings per share. McKesson’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts expect that McKesson Corporation will post 44.28 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be issued a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s payout ratio is presently 8.53%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Evercore reaffirmed an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. JPMorgan Chase & Co. cut their price objective on McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen raised McKesson from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. UBS Group lifted their price objective on McKesson from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings lowered McKesson from a “buy (b+)” rating to a “buy (b)” rating in a report on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $968.87.

Hedge Funds Weigh In On McKesson

Institutional investors and hedge funds have recently bought and sold shares of the stock. University of Texas Texas AM Investment Management Co. purchased a new position in McKesson during the fourth quarter valued at $25,000. Swiss RE Ltd. purchased a new position in McKesson during the fourth quarter valued at $26,000. GGM Financials LLC purchased a new position in McKesson during the third quarter valued at $25,000. State of Wyoming purchased a new position in McKesson during the second quarter valued at $29,000. Finally, Hopwood Financial Services Inc. purchased a new position in McKesson during the third quarter valued at $31,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.